Benzinga | Apr 30, 2021 11:16AM EDT

Credit Suisse Maintains Outperform on Teladoc Health, Lowers Price Target to $264

Credit Suisse analyst Jailendra Singh maintains Teladoc Health (NYSE:TDOC) with a Outperform and lowers the price target from $300 to $264.